Clinical Trial ProgressThe expansion of the trial to include more patients and additional sites in Europe enhances the company's footprint in the basal cell carcinoma space, potentially attracting partners.
Market OpportunityThe expansion into equine treatment of squamous cell carcinoma could represent a significant market opportunity, potentially reaching $250 million.
Product DevelopmentThe Antev acquisition deal will bring on board Teverelix, a next-generation GnRH antagonist that diversifies the Medicus pipeline and adds unlocked value potential.